2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168966
    PDE2 inhibitor 6 2097493-39-3 98%
    PDE2 inhibitor 6 (Compound 1) is the orally active inhibitor for phosphodiesterase (PDE) that inhibits PDE2A, PDE3B, and PDE10A2 with IC50s of 0.95 nM, 6.17 μM (pIC50=5.21) and 87.1 nM (pIC50=7.06), respectively. PDE2 inhibitor 6 modulates the activity of AMPA receptor, enhance the synaptic plasticity and promotes the learning and memory function in rats models. PDE2 inhibitor 6 can cross blood-brain barrier.
    PDE2 inhibitor 6
  • HY-168977
    Inidascamine 903884-71-9 98%
    Inidascamine is the modulator for cholinergic, glutamatergic, and GABAB receptor, and can be used for researchs of schizophrenia.
    Inidascamine
  • HY-168986
    Moxetomidate 1567838-90-7 98%
    Moxetomidate is a GABAA receptor agonist with hypnotic effect.
    Moxetomidate
  • HY-168988
    Olisutrigine bromide 1393836-45-7 98%
    Olisutrigine bromide is a sodium channel blocker, which can be used as analgesics.
    Olisutrigine bromide
  • HY-168997
    CB1R agonist 1 98%
    CB1R agonist 1 (Compound '1350') is a potent full agonist of the cannabinoid-1 receptor (CB1R), with a Ki value of 0.95 nM. CB1R agonist 1 exhibits significant pain-reducing effects in multiple pain models, including acute heat pain, inflammatory pain, and neuropathic pain.
    CB1R agonist 1
  • HY-169001
    5-HT2A/5-HT2C inverse agonist 1 2718990-76-0 98%
    5-HT2A/5-HT2C inverse agonist 1 is a potent and dual 5-HT2A and 5-HT2C receptor inverse agonist with a hERG inhibitions, thus avoiding cardiovascular risks. 5-HT2A/5-HT2C inverse agonist 1 shows significant antipsychotic efficacy in the MK-801 (HY-15084B)-induced mouse model. 5-HT2A/5-HT2C inverse agonist 1 is promising for research of psychosis.
    5-HT2A/5-HT2C inverse agonist 1
  • HY-169022
    4-FPBUA 2089636-93-9 98%
    4-FPBUA is a semisynthetic analog of usnic acid (HY-W015883) that can enhance cellular blood-brain barrier (BBB) function and increase the transport of Amyloid β (Aβ) across monolayer cells. 4-FPBUA is also an inhibitor of mTOR, capable of enhancing cellular Autophagy, thereby reversing BBB disruption in vivo and being utilized in research for Alzheimer's disease.
    4-FPBUA
  • HY-169024
    GSK-3β inhibitor 19 98%
    GSK-3β inhibitor 19 (compound 36) is a GSK-3β inhibitor, with IC50 of 70 nM. GSK-3β inhibitor 19 can be used in anti-inflammatory and Alzheimer's disease related research.
    GSK-3β inhibitor 19
  • HY-169025
    ADH-353 2711712-81-9 98%
    ADH-353 can inhibit Aβ fibrillation and reduce Aβ-induced cytotoxicity in SH-SY5Y and N2a cells. ADH-353 can be used in Alzheimer's disease-related research.
    ADH-353
  • HY-169038
    11(Z),14(Z)-Eicosadienoic acid ethanolamide 162758-92-1 98%
    11(Z),14(Z)-Eicosadienoic acid ethanolamide (Compound 3) is an ethanolamide-conjugated form of 11(Z),14(Z)-Eicosadienoic acid (HY-149589). 11(Z),14(Z)-Eicosadienoic acid ethanolamide inhibits the inactivating transport of an endogenous cannabinoid substance with an IC50 value of 10.6 μM. 11(Z),14(Z)-Eicosadienoic acid ethanolamide can be used for research of neuropsychiatric conditions.
    11(Z),14(Z)-Eicosadienoic acid ethanolamide
  • HY-169080
    ABCA1 inducer 1 2839627-76-6 98%
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4.
    ABCA1 inducer 1
  • HY-169103
    Neuroprotective agent 5 98%
    Neuroprotective agent 5 (compound 28) is a brain permeabilizing agent with anti-neuritis, anti-oxidative damage and neuroprotective effects. Neuroprotective agent 5 exhibits a potent NO inhibitory effect (EC50=0.49 μM), inhibits the release of proinflammatory factors PGE2 and TNF-α, downregulates the expression of iNOS and COX-2 proteins, and promotes the polarization of BV-2 cells from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In addition, Neuroprotective agent 5 can also inhibit acetylcholinesterase (AChE) activity and Aβ42 aggregation in a dose-dependent manner. Neuroprotective agent 5 can be used for the study of Alzheimer's disease.
    Neuroprotective agent 5
  • HY-169107
    RIPK1-IN-25 98%
    RIPK1-IN-25 (WL8) is a blood-brain permeable RIPK1 inhibitor with EC50 and Kd values are 19.9 and 25 nM, respectively. RIPK1-IN-25 can be used in the study of neurometabolic diseases.
    RIPK1-IN-25
  • HY-169136
    U 101958 170856-57-2 98%
    U 101958 is full Dopamine D4 receptor agonist, with a pEC50 of 8.7 in HEK293/D4 cells .
    U 101958
  • HY-169156
    HDAC6-IN-49 98%
    HDAC6-IN-49 (Compound 3) is an inhibitor for HDAC with IC50 of 0.012 and 0.735 μM for HDAC6 and HDAC1. HDAC6-IN-49 also exhibits inhibitory activities against MAO-B, cholinesterase (ChE), histamine receptor (H3R) and serotonin 6 receptor (5-HT6R). HDAC6-IN-49 exhibits neuroprotective efficacy on SH-SY5Y cell. HDAC6-IN-49 improves cognitive function and locomotor ability in Drosophila Parkinson's disease models and in C. elegans Alzheimer's disease models.
    HDAC6-IN-49
  • HY-169157
    HDAC6-IN-50 3060094-56-3 98%
    HDAC6-IN-50 (Compound 4) is a potent HDAC6 inhibitor with an IC50 of 35 nM. HDAC6-IN-50 can be used for the study of Parkinson's disease (PD) and Alzheimer's disease (AD) research.
    HDAC6-IN-50
  • HY-169162
    hBChE-IN-3 98%
    hBChE-IN-3 (compound 30) is a combination of carbonic anhydrase (CA) activator and cholinesterase (ChE) inhibitor with IC50 values of 7.4 and 1.9 nM for AchE and BchE, respectively. hBChE-IN-3 can be used in the study of neurodegeneration and psychiatric disorders.
    hBChE-IN-3
  • HY-169163
    BChE-IN-36 98%
    hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with KA values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC50 values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders.
    BChE-IN-36
  • HY-169178
    VU6016235 2344787-70-6 98%
    VU6016235 is a highly selective, orally available, positive allosteric modulator of the M4 mAChR with in vivo inhibitory potency in animal models of psychosis..
    VU6016235
  • HY-169193
    Azocarnil 98%
    Azocarnil is a GABAergic agonist-potentiator. Azocarnil can be used in neurological research.
    Azocarnil
Cat. No. Product Name / Synonyms Application Reactivity